

Sub. Form PTO-1449  <b>INFORMATION DISCLOSURE IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>  OPIE JC87 APR 15 2004 FAX 1-800-787-2536 Sheet 1 of 1	Docket Number <b>HYZ-069CN (47508-530)</b>	Application Number <b>09/837,806</b>
	Applicant <b>Agrawal</b>	
	Filing Date <b>4/18/2001</b>	Group Art Unit <b>1635</b>

## U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JZ	5,652,355	7/29/1997	Metelev, et al.			
JZ	5,652,356	7/29/1997	Agrawal			
	5,801,154	9/1/1998	Baracchini, et al.			
	6,608,035	8/19/2003	Agrawal, et al.			
	6,645,943	11/11/2003	Agrawal, et al.			

## Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)**

EXAMINER	DATE CONSIDERED
	6/4/04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

INFORMATION DISCLOSURE  
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

2

OF

3

Docket Number  
HYZ-069CN  
(47508.530)Application Number  
09/837,806Applicant  
AgrawalFiling Date  
April 18, 2001Group Art Unit  
1635

A14	Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" in <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> , (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61
A15	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> , pp. 1-17
A16	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" <i>Exp. Opin. Ther. Patents</i> 7(10):1175-1182
A17	Database CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1
A18	Froehler (1993) "Oligodeoxynucleotide Synthesis," <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 63-80
A19	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeutic Agents" <i>J. Cell. Physiol.</i> 181:251-257
A20	Gewirtz et al. (1996) "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver On Its Promise," <i>Proc. Natl. Acad. Sci. USA</i> 93:3161-3163
A21	Goodchild et al. (1988) "Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 85:5507-5511
A22	Harrison et al. (1991) "Determination of the Secondary Structure of the Packaging Signal of HIV-1" in <i>RNA Tumor Viruses</i> (Coffin et al., eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 235
A23	Iyer et al. (1995) "A Novel Nucleoside Phosphoramidite Synthon Derived From 1R, 2S-Ephedrine," <i>Tetrahedron: Asymmetry</i> 6(5):1051-1054
A24	Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> 374:546-549
A25	Lisziewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides: An <i>In Vitro</i> Model for Treatment", <i>Proc. Natl. Acad. Sci. USA</i> 89:11209-11213
A26	Lisziewicz et al. (1993) "Long-Term Treatment of Human Immunodeficiency Virus-Infected Cells with Antisense Oligonucleotide Phosphorothioates", <i>Proc. Natl. Acad. Sci. USA</i> 90:3860-3864
A27	Lisziewicz et al. (1994) "Antisense Oligodeoxynucleotide Phosphorothioate Complementary to Gag mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Cells", <i>Proc. Natl. Acad. Sci. USA</i> 91:7942-7946
A28	Matsukura et al. (1988) "Synthesis of Phosphorothioate Analogues of Oligodeoxyribonucleotides and Their Antiviral Activity Against Human Immunodeficiency Virus (HIV)," <i>Gene</i> 72:343-347
A29	Matsukura et al. (1989) "Regulation of Viral Expression of Human Immunodeficiency Virus <i>In Vitro</i> by an Antisense Phosphorothioate Oligodeoxynucleotide Against <i>rev</i> (ar/trs) in Chronically Infected Cells," <i>Proc. Natl. Acad. Sci. USA</i> 86:4244-4248
A30	Matsukura et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Towards Clinical Application," in <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> (Wickstrom, ed.), Wiley-Liss, Inc., pp. 159-178
A31	Metelev et al. (1998) "HPLC of Oligodeoxyribonucleoside Phosphorothioates", Abstract No. 151268f, <i>Chemical Abstracts</i> , 128(13):272
A32	Metelev, et al. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothioates" <i>Russian Journal of Bioorganic Chemistry</i> , 23(9):673-677, Translated from <i>Bioorganicheskaya Khimiya</i> 23(9):742-746
A33	Milligan, et al. (1993) "Current Concepts in Antisense Drug Design", <i>Journal of Medicinal Chemistry</i> , 36(14):1923-1937
A34	Milner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," <i>Nature Biotech.</i> 15:537-541
A35	Rojanasakul (1996) "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," <i>Adv. Drug Del. Rev.</i> Vol. 18:115-131
A36	Sarin et al. (1988) "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85:7448-7451
A37	Sonneaux (1994) "Protecting Groups in Oligonucleotide Synthesis," <i>Methods in Molecular Biology</i> , Vol. 26: <i>Protocols for Oligonucleotide Conjugates</i> (Agrawal, ed.), pp. 1-71
A38	Tang et al. (1993) "Self-Stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity," <i>Nucleic Acids Res.</i> 21(11):2729-2735
A39	Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90(4):543-584

EXAMINER

DATE CONSIDERED/

6/3/04

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Sub. Form PTO-1449				Docket Number <b>HYZ-069CN</b> (47508.530)	Application Number <b>09/837,806</b>
<b>INFORMATION DISCLOSURE IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Applicant <b>Agrawal</b>	
Sheet	1	OF	3	Filing Date <b>April 18, 2001</b>	Group Art Unit <b>1635</b>

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
3	4,309,404	01/05/82	DeNeale et al.			
3	4,309,406	01/05/82	Guley et al.			
	4,556,552	12/03/85	Porter et al.			
	4,704,295	11/03/87	Porter et al.			
✓	5,627,277	05/06/97	Cohen et al.			

Foreign Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
3	WO 94/08004	04/14/94	PCT			
3	WO 95/18813	07/13/95	PCT			
	WO 96/12497	05/02/96	PCT			
	WO 97/06662	02/27/97	PCT			
✓	WO 98/40058	9/17/1998	PCT			

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
3	A1	Agrawal et al. (1987) "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymic Degradation," <i>Tetrahedron. Lett.</i> 28(31):3539-3542
3	A2	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus, <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083
✓	A3	Agrawal et al. (1989) "Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically Infected Cells by Antisense Oligodeoxynucleotides and Their Phosphorothioate Analogues," <i>Proc. Natl. Acad. Sci. USA</i> 86:7790-7794
✓	A4	Agrawal (1991) "Antisense Oligonucleotides: A Possible Approach for Chemotherapy of Aids", in <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> , (Wickstrom, ed.) Wiley-Liss, Inc., pp. 143-158
✓	A5	Agrawal (1992) "Antisense Oligonucleotides as Antiviral Agents," <i>Trends in Biotechnology</i> 10:152-158
✓	A6	Agrawal et al. (1992) "Cellular Uptake and Anti-HIV Activity of Oligonucleotides and Their Analogs," <i>Gene Regulation: Biology of Antisense RNA and DNA</i> (Erickson and Izant, eds.) Raven Press Ltd., New York, pp. 273-283
✓	A7	Agrawal, et al. (1992) "GEM'91 - An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", <i>Antisense Res. Dev.</i> 2:261-266
✓	A8	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", <i>J. Biotech. in Healthcare</i> , 1(2):167-182.
✓	A9	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", <i>Clin. Pharmacokinet.</i> 28(1):7-16
✓	A10	Agrawal et al. (1995) "Absorption, Tissue Distribution and <i>In Vivo</i> Stability in Rats of a Hybrid Antisense Oligonucleotide Following Oral Administration," <i>Biochem. Pharmacol.</i> 50(4):571-576
✓	A11	Agrawal (1996) "Preface" in <i>Methods in Molecular Medicine: Antisense Therapeutics</i> (Agrawal,ed.) pp. v-vii
✓	A12	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <i>Handbook of Experimental Pharmacology</i> , Vol. 131: <i>Antisense Research and Application</i> , Springer-Verlag, pp. 525-543
✓	A13	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," <i>Biochimica et Biophysica Acta</i> 1489:53-68

EXAMINER 3	DATE CONSIDERED 6/4/04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subt. Form PTO-1449				Docket Number <b>HYZ-069CN (47508.530)</b>	Application Number <b>09/837,806</b>
INFORMATION DISCLOSURE IN AN APPLICATION  <i>(Use several sheets if necessary)</i>				Applicant <b>Agrawal</b>	
Sheet	3	OF	3	Filing Date <b>April 18, 2001</b>	Group Art Unit <b>1635</b>

EXAMINER 	DATE CONSIDERED 6/4/04
---	---------------------------